BioSim™ Pembrolizumab (Human) ELISA Kit

Pembrolizumab is an antibody-drug that targets the cell surface receptor programmed cell death protein 1 (PD-1) found on T cells. By preventing the binding of its ligands (PD-L1 and PD-L2), pembrolizumab induces an antitumor immune response. Upregulation of PD-1 ligands is a mechanism for tumors to evade antitumor immune response; when PD-1 binds its ligand, the T cell receives an inhibitory signal leading to T cell anergy and blockade of the anti-tumor immune response. Instead of directly targeting tumor tissue to induce tumor cell death, pembrolizumab acts as a checkpoint inhibitor to stimulate immune responses to eliminate cancer cells. BioSim™ Pembrolizumab ELISA kit has been developed for specific quantification of Pembrolizumab concentration in human serum or plasma with high sensitivity and reproducibility.

Alternate Name: PD1, PD-1, CD279, SLEB2, hPD-1, hPD-l, hSLE1, PDCD1, CAS 1374853-91-4

Tag Line: A Sandwich ELISA kit for the quantitative measurement of free Pembrolizumab in human serum or plasma.

Summary: N/A

Detection Method: Absorbance (450 nm)

Sample Type: Human serum and plasma

Species Reactivity: Human

Applications: This ELISA kit is used for quantitative measurement of Pembrolizumab in human serum and plasma

Features & Benefits: • Easy, convenient, sensitive and time-saving method to measure the level of Pembrolizumab in human serum and plasma. • Detection Range: 30 - 1000 ng/ml • Sensitivity: 10 ng/ml • Assay Precision: Intra-Assay: CV < 15%; Inter-Assay: CV < 15% (CV (%) = SD/mean X 100) • Recovery rate: 85 – 115% with normal human serum samples with known concentrations • Cross Reactivity: There is no cross reaction with native serum immunoglobulins and tested monoclonal antibodies such as infliximab (Remicade®), adalimumab (Humira®) , etanercept (Enbrel®), bevacizumab (Avastin®) and trastuzumab (Herceptin®)